Abacavir, Dolutegravir and Lamivudine Dispersible Tablets (60 mg/5 mg/30 mg)

Inclusion Criteria - Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified: * 18 to 55 years old. * Males and/or females not of child-bearing potential. * Each subject is required to weigh at least 50 kg (110 lbs) for men and 48 kg (106 lbs) for women and have a Body Mass Index (BMI) value less than or equal to 30.0 kg/m2 but greater than or equal to 19.0 kg/m2. * Adequate venous access in both arms. * Only non-tobacco/non-nicotine subjects. * Able to understand and sign the written Informed Consent Form. * Willing to follow the protocol requirements and comply with protocol restrictions. * All subjects should be judged by the Principal Investigator or Medical Sub- Investigator as normal and healthy during a pre-study medical evaluation performed within 28 days of the initial dose of study medication. Exclusion Criteria - Subject candidates must not be enrolled in the study if subject meet any of the following criteria: * Institutionalized subjects. * Social Habits, Medications and Diseases will be evaluated. * Use of certain foods and processed candies, gums food/drinks that contain sugar alcohols. * Liver function tests (ALT, AST and total bilirubin). * Subjects who are positive for the HLA-B\*5701 allele. * Subjects having Modified Patient Health Questionnaire (PHQ)-12 questionnaire score \> 4. * Subject has a creatinine clearance \< 90 mL/min, as determined by the Cockroft-Gault equation. * Any reason which, in the opinion of the Principal Investigator or Medical Sub- Investigator, would prevent the subject from safely participating in the study. * Intolerance to venipuncture. * Donation or loss of blood or plasma. * Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication. * Any food allergy, intolerance, restriction or special diet that, in the opinion of the Principal Investigator or Medical Sub-Investigator, could contraindicate the subject's participation in this study. * Allergy or hypersensitivity to abacavir, dolutegravir, lamivudine, other related products, or any inactive ingredients.